Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy ...
[IMAGES BELOW] Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor ...
IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell’s Bria-OTS ...
52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard ...
Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 ...
Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study ...
PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ ...
Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage setting Phase ...
Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in ...
Accessibility Tools